B+L Archives - Insight

Bausch + Lomb eyes AU$1.2 billion in IPO

Myles Hume — Mon, 02 May 2022 06:00:51 +0000

B+L could have a market value of US$8.4 billion (AU$11.9 b).

Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has filed to raise up to US$840 million (AU$1.2 billion) in an initial public offering (IPO). On
Read More

The post Bausch + Lomb eyes AU$1.2 billion in IPO appeared first on Insight.

Eyecare spin-off Bausch + Lomb files for IPO

Myles Hume — Mon, 17 Jan 2022 06:00:25 +0000

AcuFocus believes believes B+L is best positioned to educate eye doctors about the IC-8 Apthera lens.

Almost 18 months since its parent company announced Bausch + Lomb (B+L) would be spun off as a pure-play eye health company, the entity has filed for an initial public offering (IPO) on the New York and
Read More

The post Eyecare spin-off Bausch + Lomb files for IPO appeared first on Insight.

Rethinking what’s possible with the enVista IOL

Myles Hume — Fri, 07 May 2021 02:00:01 +0000

The enhanced enVista lens material enables the lens to unfold much faster.

Bausch + Lomb’s latest version of the enVista monofocal recently became available to Australian and New Zealand surgeons along with a new pre-loaded delivery system. Early adopters discuss
Read More

The post Rethinking what’s possible with the enVista IOL appeared first on Insight.

TGA approves ‘breakthrough’ B+L contact lens

Myles Hume — Mon, 24 Aug 2020 03:39:15 +0000

The TGA took just two weeks to approve the contact lens.

Bausch + Lomb has obtained regulatory approval to supply its new Ultra One Day daily disposable silicone hydrogel (SiHy daily) contact lenses in Australia. The new lens design was recently cleared by the
Read More

The post TGA approves ‘breakthrough’ B+L contact lens appeared first on Insight.